125 related articles for article (PubMed ID: 8555378)
1. L-DOPA and psychosis: evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone.
Carey RJ; Pinheiro-Carrera M; Dai H; Tomaz C; Huston JP
Biol Psychiatry; 1995 Nov; 38(10):669-76. PubMed ID: 8555378
[TBL] [Abstract][Full Text] [Related]
2. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
[TBL] [Abstract][Full Text] [Related]
3. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
4. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
7. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
8. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
[TBL] [Abstract][Full Text] [Related]
9. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
Biggs CS; Fisher A; Starr MS
Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
[TBL] [Abstract][Full Text] [Related]
10. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
11. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
12. Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
Glavan G
Brain Res; 2008 Oct; 1236():216-24. PubMed ID: 18721798
[TBL] [Abstract][Full Text] [Related]
13. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
14. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
[TBL] [Abstract][Full Text] [Related]
15. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
Joyce JN; Der TC; Renish L; Osredkar T; Hagner D; Reploge M; Sakakibara S; Ueda S
Exp Neurol; 2004 May; 187(1):178-89. PubMed ID: 15081599
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
17. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
18. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
[TBL] [Abstract][Full Text] [Related]
19. Pentobarbital inhibits L-DOPA-induced dopamine increases in the rat striatum: An in vivo microdialysis study.
Adachi YU; Yamada S; Satomoto M; Watanabe K; Higuchi H; Kazama T; Doi M; Sato S
Brain Res Bull; 2006 May; 69(5):593-6. PubMed ID: 16647588
[TBL] [Abstract][Full Text] [Related]
20. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]